CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector T-cell inhibition and regulatory T-cell expansion

Diabetes

Volumn 57, Issue 10, 2008, Pages 2672-2683

  Rigby, Mark R ^a,b   Trexler, Alison M ^a   Pearson, Thomas C ^a,b   Larsen, Christian P ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BASILIXIMAB; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; ICOS MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PD1 MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; CD40 LIGAND; CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELL EXPANSION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; EFFECTOR CELL; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; RECIPIENT; REGULATORY T LYMPHOCYTE; SCID MOUSE; T LYMPHOCYTE; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOUSE MUTANT; PANCREAS ISLET BETA CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; CD40 LIGAND; CYTOKINES; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INSULIN-SECRETING CELLS; MICE; MICE, SCID; MODELS, BIOLOGICAL; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 58149347688     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1712     Document Type: Article

References (46)

1. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker- Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434-438, 1996
2. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, Mordes JP, Rossini AA: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad SciUSA 92:9560-9564, 1995
3. Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh MH:CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 62:1942-1945, 1996 4. Adams AB, Shirasugi N, Durham MM, Strobert E, Anderson D, Rees P, Cowan S, Xu H, Blinder Y, Cheung M, Hollenbaugh D, Kenyon NS, Pearson TC, Larsen CP: Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51:265-270, 2002
4. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5:1298-1302,1999
5. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA: Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 101:2446-2455, 1998
6. Adler SH, Turka LA: Immunotherapy as a means to induce transplantation tolerance. Curr Opin Immunol 14:660-665, 2002
7. Solomon M, Sarvetnick N: The pathogenesis of diabetes in the NOD mouse. Adv Immunol 84:239-264, 2004
8. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N: CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 159:4620-4627, 1997
9. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181:1145-1155, 1995
10. Berney T, Pileggi A, Molano RD, Poggioli R, Zahr E, Ricordi C, Inverardi L: The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation 76: 1669-1674, 2003
11. Molano RD, Pileggi A, Berney T, Poggioli R, Zahr E, Oliver R, Ricordi C, Rothstein DM, Basadonna GP, Inverardi L: Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes 52:957-964, 2003
12. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-440, 2000
13. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA: Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 114:979-987, 2004
14. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA: CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285-293,1996
15. Eshima K, Mora C, Wong FS, Green EA, Grewal IS, Flavell RA: A crucial role of CD4 T cells as a functional source of CD154 in the initiation of insulin-dependent diabetes mellitus in the non-obese diabetic mouse. Int Immunol 15:351-357, 2003
16. Bluestone JA, Boehmer H: Regulatory T cells. Semin Immunol 18:77, 2006 18. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6:114, 2000
17. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028, 2006
18. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA: Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155:170-181, 2006
19. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698, 2002
20. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L: Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608, 2005
21. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D: Genetic control of diabetes progression. Immunity 7:873-883, 1997
22. Suri A, Shimizu J, Katz JD, Sakaguchi S, Unanue ER, Kanagawa O: Regulation of autoimmune diabetes by non-islet-specific T cells: a role for the glucocorticoid-induced TNF receptor. Eur J Immunol 34:447-454, 2004. 25. Katz JD, Wang B, Haskins K, Benoist C, Mathis D: Following a diabetogenic T cell from genesis through pathogenesis. Cell 74:1089-1100, 1993
23. + T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 199:1479-1489, 2004
24. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA: Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest 116:2252-2261, 2006
25. Judkowski V, Pinilla C, Schroder K, Tucker L, Sarvetnick N, Wilson DB: Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol 166: 908-917, 2001
26. Kurrer MO, Pakala SV, Hanson HL, Katz JD: Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad SciUSA94:213-218, 1997
27. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D: Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad SciUSA93:2260-2263, 1996
28. Anderson MS, Bluestone JA: The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23:447-485, 2005
29. Rossini AA, Greiner DL, Mordes JP: Induction of immunologic tolerance for transplantation. Physiol Rev 79:99-141, 1999
30. Garcia S, DiSanto J, Stockinger B: Following the development of a CD4 T cell response in vivo: from activation to memory formation. Immunity 11:163-171, 1999
31. Yadav D, Sarvetnick N: Cytokines and autoimmunity: redundancy defines their complex nature. Curr Opin Immunol 15:697-703, 2003
32. + regulatory T cells control autoimmunity? Curr Opin Immunol 17:638-642, 2005
33. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D: Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189:331-339, 1999
34. Jaakkola I, Jalkanen S, Hanninen A: Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. Eur J Immunol 33:3255-3264, 2003
35. King C, Ilic A, Koelsch K, Sarvetnick N: Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265-277, 2004
36. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA: Homeo- static proliferation is a barrier to transplantation tolerance. Nat Med 10:87-92, 2004
37. Ford ML, Koehn BH, Wagener ME, Jiang W, Gangappa S, Pearson TC, Larsen CP: Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 204: 299-309, 2007
38. Marleau AM, Sarvetnick N: T cell homeostasis in tolerance and immunity. J Leukoc Biol 78:575-584, 2005
39. Jahromi MM, Eisenbarth GS: Cellular and molecular pathogenesis of type 1A diabetes. Cell Mol Life Sci 64:865-872, 2007
40. Baccala R, Theofilopoulos AN: The new paradigm of T-cell homeostatic proliferation-induced autoimmunity. Trends Immunol 26:5-8, 2005 44. Prlic M, Blazar BR, Khoruts A, Zell T, Jameson SC: Homeostatic expansion occurs independently of costimulatory signals. J Immunol 167:5664-5668, 2001
41. Fontenot JD, Rudensky AY: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6:331-337, 2005
42. Campbell DJ, Ziegler SF: FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 7:305-310, 2007
43. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L: Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad SciUSA104:6335-6340, 2007
44. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA: Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203:2737-2747, 2006
45. + regulatory T cells. J Immunol 177:6603-6612, 2006
46. Mordes JP, Bortell R, Doukas J, Rigby M, Whalen B, Zipris D, Greiner DL, Rossini AA: The BB/Wor rat and the balance hypothesis of autoimmunity. Diabete Metab Rev 12:103-109, 1996